JP2000504716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000504716A5 JP2000504716A5 JP1997529120A JP52912097A JP2000504716A5 JP 2000504716 A5 JP2000504716 A5 JP 2000504716A5 JP 1997529120 A JP1997529120 A JP 1997529120A JP 52912097 A JP52912097 A JP 52912097A JP 2000504716 A5 JP2000504716 A5 JP 2000504716A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/602,272 US7608262B2 (en) | 1996-02-16 | 1996-02-16 | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
| US08/602,272 | 1996-02-16 | ||
| PCT/GB1997/000435 WO1997030088A2 (en) | 1996-02-16 | 1997-02-17 | Methods of treating vascular disease with tnf antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000504716A JP2000504716A (ja) | 2000-04-18 |
| JP2000504716A5 true JP2000504716A5 (enExample) | 2004-11-18 |
Family
ID=24410695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9529120A Ceased JP2000504716A (ja) | 1996-02-16 | 1997-02-17 | Ｔｎｆアンタゴニストを用いた血管障害の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7608262B2 (enExample) |
| EP (2) | EP1460087B1 (enExample) |
| JP (1) | JP2000504716A (enExample) |
| AT (2) | ATE331736T1 (enExample) |
| CA (1) | CA2246297C (enExample) |
| DE (2) | DE69726123T3 (enExample) |
| DK (1) | DK0882067T3 (enExample) |
| ES (1) | ES2213816T5 (enExample) |
| PT (1) | PT882067E (enExample) |
| WO (1) | WO1997030088A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12036232B2 (en) | 2016-11-23 | 2024-07-16 | Mayo Foundation For Medical Education And Research | Particle-mediated delivery of biologics |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1170017A1 (en) * | 1997-05-12 | 2002-01-09 | The Kennedy Institute Of Rheumatology | Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition |
| US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| USRE45976E1 (en) | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
| US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| AU763575B2 (en) * | 1999-04-02 | 2003-07-24 | Immunex Corporation | Use of soluble tumor necrosis factor receptor for treatment heart failure |
| CA2399436A1 (en) * | 2000-02-10 | 2001-08-16 | Loran Marie Killar | Method of treating or inhibiting cellular injury or cell death |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| DK2438913T3 (da) * | 2002-03-20 | 2020-06-22 | Univ Maryland | Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20100168542A1 (en) | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7778680B2 (en) * | 2003-08-01 | 2010-08-17 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
| US20060045902A1 (en) * | 2004-09-01 | 2006-03-02 | Serbousek Jon C | Polymeric wrap for in vivo delivery of osteoinductive formulations |
| ATE486606T1 (de) * | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür |
| AU2005287090A1 (en) * | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
| US8236306B2 (en) * | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| WO2008089103A2 (en) | 2007-01-12 | 2008-07-24 | University Of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
| WO2008098160A1 (en) * | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
| CA3065983C (en) | 2007-06-22 | 2022-07-26 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of ncca-atp channels for therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863531A (en) * | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| WO1991000092A1 (en) * | 1989-06-13 | 1991-01-10 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
| GB9007762D0 (en) | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
| DE4037604A1 (de) | 1990-04-25 | 1991-10-31 | Bayer Ag | Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen |
| GB9024738D0 (en) | 1990-11-14 | 1991-01-02 | Erba Carlo Spa | A new method of treatment of tumor necroisis factor(tnf)-related diseases |
| NZ240644A (en) * | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| CA2736076A1 (en) | 1991-03-18 | 1992-09-19 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| WO1993011793A1 (en) * | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
| US5547979A (en) * | 1992-03-30 | 1996-08-20 | Smithkline Beecham | TNF inhibition |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| GB9223904D0 (en) | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
| EP1004312A1 (en) | 1993-07-30 | 2000-05-31 | Kennedy Institute Of Rheumatology | Method for treating multiple sclerosis |
| GB9401129D0 (en) | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
| GB2289218A (en) | 1994-05-06 | 1995-11-15 | Merck & Co Inc | Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor |
| WO1996021447A1 (en) | 1995-01-09 | 1996-07-18 | Otsuka Pharmaceutical Company, Limited | Use of carbostyril compounds for inhibition of tnf-alpha |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
-
1996
- 1996-02-16 US US08/602,272 patent/US7608262B2/en not_active Expired - Fee Related
-
1997
- 1997-02-17 DE DE69726123T patent/DE69726123T3/de not_active Expired - Lifetime
- 1997-02-17 PT PT97903485T patent/PT882067E/pt unknown
- 1997-02-17 EP EP03025867A patent/EP1460087B1/en not_active Expired - Lifetime
- 1997-02-17 JP JP9529120A patent/JP2000504716A/ja not_active Ceased
- 1997-02-17 EP EP97903485A patent/EP0882067B2/en not_active Expired - Lifetime
- 1997-02-17 CA CA2246297A patent/CA2246297C/en not_active Expired - Fee Related
- 1997-02-17 AT AT03025867T patent/ATE331736T1/de not_active IP Right Cessation
- 1997-02-17 DE DE69736258T patent/DE69736258D1/de not_active Expired - Lifetime
- 1997-02-17 AT AT97903485T patent/ATE254140T1/de not_active IP Right Cessation
- 1997-02-17 DK DK97903485T patent/DK0882067T3/da active
- 1997-02-17 WO PCT/GB1997/000435 patent/WO1997030088A2/en not_active Ceased
- 1997-02-17 ES ES97903485T patent/ES2213816T5/es not_active Expired - Lifetime
-
2009
- 2009-06-04 US US12/455,658 patent/US20090263388A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12036232B2 (en) | 2016-11-23 | 2024-07-16 | Mayo Foundation For Medical Education And Research | Particle-mediated delivery of biologics |